RU2006100561A - Способ лечения онкологических забелеваний - Google Patents

Способ лечения онкологических забелеваний Download PDF

Info

Publication number
RU2006100561A
RU2006100561A RU2006100561/14A RU2006100561A RU2006100561A RU 2006100561 A RU2006100561 A RU 2006100561A RU 2006100561/14 A RU2006100561/14 A RU 2006100561/14A RU 2006100561 A RU2006100561 A RU 2006100561A RU 2006100561 A RU2006100561 A RU 2006100561A
Authority
RU
Russia
Prior art keywords
patient
dna
amount
oncological diseases
treating oncological
Prior art date
Application number
RU2006100561/14A
Other languages
English (en)
Other versions
RU2313349C2 (ru
Inventor
Михаил Аркадьевич Шурдов (RU)
Михаил Аркадьевич Шурдов
Сергей Станиславович Богачев (RU)
Сергей Станиславович Богачев
Леонид Анатольевич Якубов (RU)
Леонид Анатольевич ЯКУБОВ
Владимир Алексеевич Рогачев (RU)
Владимир Алексеевич Рогачев
Валерий Петрович Николин (RU)
Валерий Петрович Николин
Нелли Александровна Попова (RU)
Нелли Александровна Попова
Анастаси Сергеевна Лихачева (RU)
Анастасия Сергеевна Лихачева
Тамара Егоровна Себелева (RU)
Тамара Егоровна Себелева
Александр Геннадиевич Шилов (RU)
Александр Геннадиевич Шилов
Наталь Сергеевна Жданова (RU)
Наталья Сергеевна Жданова
Людмила Васильевна Мечетина (RU)
Людмила Васильевна Мечетина
Оксана В чеславовна Врацких (RU)
Оксана Вячеславовна Врацких
Сергей Николаевич Серегин (RU)
Сергей Николаевич Серегин
Original Assignee
Михаил Аркадьевич Шурдов (RU)
Михаил Аркадьевич Шурдов
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Михаил Аркадьевич Шурдов (RU), Михаил Аркадьевич Шурдов filed Critical Михаил Аркадьевич Шурдов (RU)
Priority to RU2006100561/14A priority Critical patent/RU2313349C2/ru
Priority to JP2008551212A priority patent/JP2009523788A/ja
Priority to PCT/RU2006/000144 priority patent/WO2007081235A1/ru
Priority to CNA2006800538130A priority patent/CN101400357A/zh
Priority to EP06769535A priority patent/EP2002840A4/en
Publication of RU2006100561A publication Critical patent/RU2006100561A/ru
Application granted granted Critical
Publication of RU2313349C2 publication Critical patent/RU2313349C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Claims (2)

1. Способ лечения онкологических заболеваний, основанный на введении в организм пациента фрагментированной ДНК, отличающийся тем, что в качестве фрагментированной ДНК, используют фрагменты гомологической ДНК, имеющие биологически активный размер, составляющие полный геном физиологически и генетически здорового донора.
2. Способ по п.1, отличающийся тем, что количество вводимого в организм пациента фрагментированной ДНК равно или превышает количество собственно ДНК плазмы крови и тканевых жидкостей больного, но не превышает максимально допустимого количества, равного 30 мкг/мл.
RU2006100561/14A 2006-01-16 2006-01-16 Способ лечения онкологических заболеваний RU2313349C2 (ru)

Priority Applications (5)

Application Number Priority Date Filing Date Title
RU2006100561/14A RU2313349C2 (ru) 2006-01-16 2006-01-16 Способ лечения онкологических заболеваний
JP2008551212A JP2009523788A (ja) 2006-01-16 2006-03-27 腫瘍性疾患の治療用製剤
PCT/RU2006/000144 WO2007081235A1 (fr) 2006-01-16 2006-03-27 Procede de traitement de maladies cancereuses
CNA2006800538130A CN101400357A (zh) 2006-01-16 2006-03-27 治疗肿瘤疾病的方法
EP06769535A EP2002840A4 (en) 2006-01-16 2006-03-27 METHOD FOR THE TREATMENT OF ONCOLOGICAL ILLNESSES

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2006100561/14A RU2313349C2 (ru) 2006-01-16 2006-01-16 Способ лечения онкологических заболеваний

Publications (2)

Publication Number Publication Date
RU2006100561A true RU2006100561A (ru) 2007-07-27
RU2313349C2 RU2313349C2 (ru) 2007-12-27

Family

ID=38256557

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2006100561/14A RU2313349C2 (ru) 2006-01-16 2006-01-16 Способ лечения онкологических заболеваний

Country Status (5)

Country Link
EP (1) EP2002840A4 (ru)
JP (1) JP2009523788A (ru)
CN (1) CN101400357A (ru)
RU (1) RU2313349C2 (ru)
WO (1) WO2007081235A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2387456C1 (ru) * 2008-08-28 2010-04-27 Михаил Аркадьевич Шурдов Способ лечения онкологических заболеваний
IT1393331B1 (it) * 2009-02-09 2012-04-20 Graal S R L Composizioni orosolubili e/o effervescenti contenenti almeno un sale di s-adenosilmetionina (same)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5302389A (en) 1992-08-17 1994-04-12 Board Of Regents, The University Of Texas System Method for treating UV-induced suppression of contact hypersensitivity by administration of T4 endonuclease
US5470577A (en) 1993-07-07 1995-11-28 Trustees Of Boston University Stimulation of tanning by DNA fragments or single-stranded DNA
FR2710536B1 (fr) * 1993-09-29 1995-12-22 Transgene Sa Usage anti-cancéreux d'un vecteur viral comportant un gène modulateur de la réponse immunitaire et/ou inflammatoire.
SE9402642D0 (sv) * 1994-08-05 1994-08-05 Maria Anvret Gene Therapy
US5955059A (en) 1995-06-06 1999-09-21 Trustees Of Boston University Use of locally applied DNA fragments
US5731181A (en) 1996-06-17 1998-03-24 Thomas Jefferson University Chimeric mutational vectors having non-natural nucleotides
RU2234323C1 (ru) * 2003-05-27 2004-08-20 Шурдов Михаил Аркадьевич Препарат, обладающий противоопухолевым, антитоксическим и радиопротекторным действием

Also Published As

Publication number Publication date
EP2002840A2 (en) 2008-12-17
CN101400357A (zh) 2009-04-01
JP2009523788A (ja) 2009-06-25
EP2002840A4 (en) 2011-07-13
EP2002840A9 (en) 2009-04-15
WO2007081235A1 (fr) 2007-07-19
RU2313349C2 (ru) 2007-12-27

Similar Documents

Publication Publication Date Title
AU2009100401A4 (en) Method of extracting and activating adipose-derived stem cells
WO2005000245A3 (en) Compositions and methods for increasing telomerase activity
WO2005001080A3 (en) Postpartum-derived cells for use in treatment of disease of the heart and circulatory system
UA99167C2 (ru) Лечение дегенерации межреберных дисков с использованием клеток, полученных из ткани пуповины человека
EP2348103A3 (en) Methods of using regenerative cells in the treatment of peripheral vascular disease and related disorders
WO2006127007A3 (en) Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
EP2363022A3 (en) Use of oxygen antagonists for the therapeutic treatment of mammals
TW200513532A (en) VEGF traps and therapeutic uses thereof
SG146691A1 (en) Methods of preparing and using stem cell compositions and kits comprising the same
NO20045521L (no) Diarylureaderivater anvendelige for behandling av proteinkinaseavhengige sykdommer
WO2006118801A3 (en) Multi-purpose medical implant devices
BRPI0818183A2 (pt) reparo e regeneração do tecido renal usando células derivadas do tecido do cordão umbilical humano
WO2004104166A3 (en) Administration of hyaluronic acid to enhance the function of transplanted stem cells
WO2007056433A3 (en) Methods of treating tissue defects
ATE410155T1 (de) Verwendung von cyclin-d1-hemmern zur brustkrebsbehandlung
WO2005047469A3 (en) PORCINE ISOGLOBOSIDE 3 SYNTHASE PROTEIN, cDNA, GENOMIC ORGANIZATION, AND REGULATORY REGION
WO2006022612A3 (en) Methods of using regenerative cells in the treatment of stroke and related diseases and disorders
WO2003039591A3 (de) Allogene vakzine enthaltend eine ein costimulatorisches polypeptid exprimierende tumorzelle
ATE506961T1 (de) Ccn3 proteine zur behandlung und diagnose von nierenerkrankungen
RU2006100561A (ru) Способ лечения онкологических забелеваний
WO2008027238A3 (en) Induction of immunosuppression by inhibition of atm
Zhang et al. Low-dose captopril inhibits wear debris-induced inflammatory osteolysis
Du et al. Experimental vascular protective shield combined with vacuum sealing drainage prevents pressure on exposed vessels and accelerates wound repair
RU2007112025A (ru) Способ лечения онкологических заболеваний
RU2006127134A (ru) Способ лечения заболеваний

Legal Events

Date Code Title Description
RH4A Copy of patent granted that was duplicated for the russian federation

Effective date: 20080415

PC41 Official registration of the transfer of exclusive right

Effective date: 20141006

MM4A The patent is invalid due to non-payment of fees

Effective date: 20160117

NF4A Reinstatement of patent

Effective date: 20161220

MM4A The patent is invalid due to non-payment of fees

Effective date: 20200117